Bezlotoxumab

Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI) . Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention[1][2][3].

Product Specifications

CAS Number

[1246264-45-8]

Product Name Alternative

BLA761046; MBL-CDB1; MDX-1388

UNSPSC

12352203

Target

Bacterial

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bezlotoxumab.html

Purity

95.0

Solubility

H2O

Smiles

[Bezlotoxumab]

Molecular Weight

(145.54 kDa)

References & Citations

[3]Zhang Z, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015 Jan;83 (1) :405-16. |[1]Navalkele BD, et, al. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018 Jan 18;12:11-21.|[2]Johnson S, et al. Bezlotoxumab. Clin Infect Dis. 2019 Feb 1;68 (4) :699-704.